BioFire FilmArray -Model RP2.1- EZ -Respiratory Pathogen Detection Panel
The BioFire RP EZ uses a molecular syndromic approach to accurately detect and identify a wide range of pathogens—not just Flu A and Flu B. As a healthcare provider, this means your patients can receive the right treatment the first time, potentially leading to higher patient satisfaction and lower costs. And as the name implies, it’s easy and can be performed right in your office or clinic.1
Nail It With One Swab.
Because a large number of pathogens cause respiratory infections, tests that only identify Flu A and B run the risk of missing the real culprit. Many rapid influenza diagnostic tests sacrifice accuracy for speed, with sensitivities ranging from 50-70%.2
The BioFire RP EZ provides an accurate, comprehensive alternative to targeted influenza testing, and will detect a greater number of pathogens no matter the season or the time of year.3
The BioFire Respiratory Panel EZ
Sample Type: Nasopharyngeal swab
14 TARGETS IN ONE TEST
The BioFire RP EZ tests for a comprehensive set of 14 respiratory viral and bacterial pathogens. It is is a CLIA-waived version of the CE marked, FDA-cleared BioFire® FilmArray® Respiratory Panel (RP), and is designed to run on a single computer/instrument configuration (EZ Configuration) of the BioFire® FilmArray® 2.0.
Product not available outside U.S.
VIRUSES:
- Adenovirus
- Coronavirus
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza A/H1
- Influenza A/H3
- Influenza A/H1-2009
- Influenza B
- Parainfluenza Virus
- Respiratory Syncytial Virus
BACTERIA:
- Bordetella pertussis
- Chlamydophila pneumoniae
- Mycoplasma pneumoniae
Among ambulatory care visits in the U.S., only 50% of antibiotic prescriptions for acute respiratory infections were estimated to be appropriate.4 In 2016, to combat the growing threat of antibiotic resistance, the President’s National Action Plan called for a goal of reducing antibiotics prescribed for acute respiratory conditions by 50% in 2020.5 The BioFire RP EZ may help increase patient satisfaction by aiding more accurate and timely diagnoses, while potentially reducing unnecessary antibiotic prescriptions.
Traditionally, clinical care of respiratory tract infections is designed around syndromic disease management and centralized laboratory testing.6 Now laboratory testing is shifting to decentralized, near-patient settings, creating a simplified process with faster results.7 With the shift toward value-based care, you can do what is best for the patient while reducing untimely and expensive send-out tests.